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Abstract 35 
Single dose primaquine (PQ) clears mature gametocytes and reduces transmission of 36 
Plasmodium falciparum after artemisinin combination therapy. Genetic variation in CYP2D6, 37 
the gene producing the drug metabolizing enzyme cytochrome P450 2D6 (CYP2D6), 38 
influences plasma concentrations of PQ and its metabolites and is associated with PQ 39 
treatment failure in P. vivax. Using blood and saliva samples of varying quantity and quality 40 
from 8 clinical trials across Africa, (n=1076), we were able to genotype CYP2D6 for 774 41 
samples (72%). We determined whether genetic variation in CYP2D6 has implications for PQ 42 
efficacy in individuals with gametocytes at the time of PQ administration (n=554) and for 43 
safety in Glucose-6-phosphate dehydrogenase (G6PD) deficient individuals treated with PQ 44 
(n=110). Individuals with genetically inferred CYP2D6 poor/intermediate metabolizer status 45 
had higher gametocyte prevalence on day 7 or 10 post PQ compared to those with 46 
extensive/ultrarapid CYP2D6 metabolizer status (OR = 1.79 [1.10, 2.90], p = 0.018). Mean 47 
minimum haemoglobin concentration during follow-up for G6PD deficient individuals was 48 
11.8 g/dL for CYP2D6 extensive/ultrarapid metabolizers and 12.1 g/dL for CYP2D6 49 
poor/intermediate metabolizers (p = 0. 803). CYP2D6 genetically inferred metabolizer status 50 
was also not associated with anaemia following PQ treatment. (p = 0.331). We conclude that 51 
CYP2D6 poor/intermediate metabolizer status may be associated with prolonged 52 
gametocyte carriage after treatment with single low dose PQ but not with treatment safety. 53 
  54 
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Introduction 55 
With recent successes in malaria control and the move towards P. falciparum elimination, 56 
there is an increasing interest in transmission-reducing strategies. One of the tools available 57 
is single low dose (0.25 mg/kg) primaquine (PQ) added to artemisinin combination therapy 58 
(ACT). PQ is a drug in the class of 8-aminoquinolines that has been on the market for more 59 
than 70 years. In recent years, the addition of PQ to ACTs has received considerable interest 60 
because of its ability to rapidly clear mature P. falciparum gametocytes and reduce the 61 
infectious period compared to ACT alone (1-6).  62 
Cytochrome P450 2D6 (CYP2D6) is a human enzyme involved in the metabolization of 20-63 
25% of all prescribed medicines (7-10). Hundreds of different CYP2D6 alleles have been 64 
discovered, some of which influence activity of the produced enzyme (11). Bennett and 65 
colleagues first associated genetic CYP2D6 variation with relapses of P. vivax malaria after 66 
PQ treatment (12). More recently, genetic CYP2D6 variation was found to be strongly 67 
associated with an increased risk of relapses among Indonesian patients with clinical P. vivax 68 
malaria (7). There is also evidence in mice that enzymes in the CYP2D family produce the 69 
active metabolite of PQ against P. berghei liver stages (13), but metabolic activation of PQ 70 
may not be necessary to eradicate blood stages (14).  71 
The implications of genetic CYP2D6 variation for the use of PQ in P. falciparum infections 72 
have never been explored. One of the factors that has hindered widespread adoption of PQ 73 
for P. falciparum transmission-reduction is its safety profile, notably in individuals with 74 
genetic deficiencies in glucose-6-phosphate dehydrogenase (G6PD) production (12, 15-17). 75 
G6PD is an enzyme involved in the pentose phosphate pathway in human red blood cells 76 
(18), and G6PD deficiency (G6PDd) is associated with haemolysis following treatment with 77 
PQ. Despite safety concerns related to the haemolytic activity of PQ in individuals with 78 
G6PDd, a single low dose of PQ is considered safe in individuals with the most common 79 
African G6PDd variant (G6PDd A- variant) (19-21). Since genetic variation in CYP2D6 80 
influences the pharmacokinetics of single low dose PQ in humans (22), this variation may 81 
have implications for PQ efficacy or safety at doses targeting P. falciparum gametocytes.  82 
Here, we determine the impact of genetically inferred CYP2D6 metabolizer status on the 83 
gametocytocidal and haemolytic effect of single dose PQ in 8 clinical trials conducted across 84 
Africa. 85 
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Results: 86 
CYP2D6 genotyping with OpenArray technology used here requires high quality DNA, ideally 87 
50 ng/µl, a condition that was not always met. CYP2D6 genotyping was thus successful in 88 
72% (774/1076) of all samples; success varied considerably between sample types with 89 
good success rates for saliva samples (≥98%) and large volume blood samples (≥0.5mL 90 
blood; success rate ≥87%) but low success rates for different sample types (1-68%) (Table 1 91 
and Dataset S1). As a result of differences in sample collection methods between sites, 92 
genotyping was successful for ≤58% of samples from Uganda and Balonghin, Burkina Faso 93 
but for ≥80% of samples for other sites (Table 1 and Dataset S1). Inference of CYP2D6 94 
Activity Score (AS) from genotypes was successful in 68% (731/1076) of samples and 95 
presented for the different sites in Figure 1. The CYP2D6 AS inference allowed classification 96 
of sample donors as poor metabolizer (PM, activity score = 0), intermediate metabolizer 97 
(IM, activity score 0.5-1.0), extensive metabolizer (EM, activity score 1.5-2.0) or ultra-rapid 98 
metabolizer (UM, activity score >2.0). For other samples, a range of AS could be inferred 99 
that allowed classification into EM/UM classes (AS≥1.5; n=137) (Dataset S2). CYP2D6 PM 100 
status was inferred for a minority of individuals (2.6%; 19/731); CYP2D6 IM status was 101 
inferred for 38.2% of individuals (279/731).  102 
544 participants from 5 studies who had gametocytes by molecular methods on the day of 103 
initiation of treatment, completed treatment, and had complete outcome measures were 104 
included in the efficacy analysis. The prevalence of CYP2D6 PM/IM among these individuals 105 
was 31.4% (171/544) overall and ranged from 26% to 41% by study. Compared to ACT-106 
treatment alone, PQ was effective in reducing gametocyte prevalence on day 7 or 10 in both 107 
CYP2D6 EM/UM (OR = 0.20 [0.11, 0.36], p < 0.001) and CYP2D6 PM/IM individuals (OR = 108 
0.15 [0.05, 0.44], p = 0.001). Individuals with CYP2D6 PM/IM status had higher gametocyte 109 
prevalence at day 7 or 10 post PQ compared to those with CYP2D6 EM/UM status (Table 2), 110 
after adjusting for PQ dose, country and baseline gametocyte density (OR = 1.79 (1.10 – 111 
2.90), p = 0.018).  112 
For the safety analysis, PQ was administered to 110 G6PDd individuals in 7 different studies. 113 
Among these PQ-treated G6PDd individuals, 56% (62/110) were EM/UM and possibly at risk 114 
of more severe haemolysis due to increased availability of the active metabolite(s) of PQ. 115 
Pre-treatment mean Hb was 13.3 g/dL in the CYP2D6 EM/UM G6PDd individuals and 13.4 116 
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g/dL in the CYP2D6 PM/IM G6PDd individuals (p = 0.803). Mean minimum Hb during 10-28 117 
days of follow-up was 11.8 g/dL for CYP2D6 EM/UM G6PDd individuals and 12.1 g/dL for 118 
CYP2D6 PM/IM G6PDd individuals. This difference, adjusted for baseline Hb, country and 119 
primaquine dose was 0.05 g/dL (95% CI [-0.34, 0.44], p = 0. 803) and not statistically 120 
significant. One hundred individuals had Hb measurement on day 7 post-treatment: mean 121 
Hb on day 7 was 12.5 g/dL for CYP2D6 EM/UM G6PDd individuals and 12.8 g/dL for CYP2D6 122 
PM/IM G6PDd individuals (adjusted difference 0.25 g/dL; 95% CI [-0.24, 0.74], p = 0.314). 123 
24% (15/62) of CYP2D6 EM/UM G6PDd individuals experienced moderate anaemia 124 
compared to 23% (11/48) of CYP2D6 PM/IM G6PDd individuals (adjusted odds ratio 2.11 125 
95% CI [0.46, 9.72], p = 0.334). Only one G6PDd individual from Burkina Faso had severe 126 
anaemia post PQ treatment (Hb 7 g/dL at day 10); this individual was CYP2D6 EM/UM, had 127 
baseline Hb of 12.5g/dL and recovered completely by day 14 (Hb of 11.9/dL). 128 
Although CYP2D6 genotyping success was low for some sample sets, it was not associated 129 
with persisting gametocytes on day 7 or 10 (OR = 0.95 [0.65-1.38], p = 0.771) or Hb 130 
(difference = -0.83 [-1.91, 0.25], p = 0.129) in models adjusted for country, PQ dose and 131 
baseline gametocyte density.  We thus found no evidence for selection bias in our efficacy 132 
and safety outcome assessments due to variation in CYP2D6 genotyping success. 133 
  134 
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Discussion 135 
In the current study we utilized samples from clinical trials across Africa to explore the effect 136 
of genetically inferred CYP2D6 metabolizer status on PQ efficacy and safety. Compared to 137 
ACT alone, the addition of single dose PQ resulted in a marked reduction in gametocyte 138 
carriage across populations with different CYP2D6 metabolizer statuses. Nevertheless, 139 
CYP2D6 PM/IM individuals were more likely to have persisting gametocytes until day 7 or 10 140 
following initiation of treatment with ACT-PQ.  141 
Whilst the transmission-blocking effect of PQ may precede the gametocyte clearing effect 142 
and gametocytes persisting after PQ may not result in onward transmission to mosquitoes 143 
(1, 6, 23), the results of the current study suggest that the efficacy of low dose PQ may be 144 
affected by CYP2D6 metabolizer status. We previously demonstrated that PQ 145 
pharmacokinetics is influenced by genetically inferred CYP2D6 metabolizer status (22), 146 
suggesting lower concentrations of the PQ active metabolites may occur in CYP2D6 PM/IM. 147 
Whilst CYP2D6 metabolizer status and concentrations of active PQ metabolites have direct 148 
implications for P. vivax-infected patients by affecting cure rates (12), the effect for P. 149 
falciparum-infected patients is indirect: potentially increasing the number of secondary 150 
cases arising from a PQ-treated gametocyte carrier.  151 
We observed no effect of CYP2D6 metabolizer status on Hb concentrations after PQ 152 
treatment of G6PDd individuals. We hypothesized that G6PDd individuals with CYP2D6 153 
PM/IM status would be relatively protected from haemolysis, but this was not observed. 154 
Whilst we combined safety studies to maximize the number of observations in G6PDd 155 
individuals, it is possible that our study population size was insufficient to detect subtle 156 
effects on haemolysis. Inter-study variation may also have obscured effects of CYP2D6 157 
status, although study site was incorporated into our multivariate regression models.  158 
There are several limitations to this study. We worked with available samples from several 159 
clinical trials, not specifically collecting material for extensive human genotyping. The 160 
variable quality and quantity of samples affected our genotyping success rate but is unlikely 161 
to have affected the validity of our comparisons between populations with successful 162 
genotyping results. Similarly, the current study did not allow us to detect possible 163 
differences in effects between ACTs. CYP2D6 activity and PQ metabolism may be influenced 164 
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differently by dihydroartemisinin-piperaquine (DP) (24) and artemether-lumefantrine (AL) 165 
(25). Whilst we combined findings from trials with different ACTs, this is unlikely to have 166 
affected the validity of our findings and we adjusted for study effects. Another limitation is 167 
that we inferred CYP2D6 metabolizer status from the CYP2D6 genotype. There has been a 168 
series of publications describing situations where the commercially available TaqMan 169 
assays, also used here in OpenArray format, have not worked as expected, and have been 170 
redesigned (26-29). Most significantly, one assay variant detecting CYP SNPs (*15-allele, 171 
C__32407245_40) suffers from interference from the sequence of the pseudogene CYP2D7 172 
to the extent that these results were not included in the analysis (27). Some additional 173 
assays have been replaced with new and improved ones during the course of this study (*7-174 
assay C__32388575_30 with C__32388575_A0, *8-assay C_30634117C_20 with 175 
C_30634117C_K0, and *14-assay C_30634117D_30 with C_30634117D_M0) (30). In 176 
addition, copy number variation (CNV) assay targeting intron 2 (Hs04083572_cn) may not 177 
always give the correct result due to intronic polymorphisms and CNV assays in general only 178 
work with high sample quality (and not after product pre-amplification). These challenges in 179 
genetic analysis underline the complexity of the locus and the need for more sequencing of 180 
CYP2D6. Especially in African populations for which pharmacogenetic data is lacking, 181 
additional data are needed (31). Such future studies may purposefully collect select samples 182 
for human genotyping. In our studies 0.5-1mL EDTA blood, or Oragene saliva samples 183 
resulted in high genotyping success rates (Table 1). Another option is to perform CYP2D6 184 
phenotyping experiments, where a probe substrate to assess CYP2D6 activity is used. 185 
Although substrate specificity may complicate extrapolation of such assays to PQ 186 
metabolism, an unquestionable advantage of phenotyping is that it would take into 187 
consideration environmental factors influencing CYP2D6 activity. These include, but are not 188 
limited to co-morbidities, concomitant medication and food intake (32, 33).  189 
Despite limitations, including the modest number of observations from individuals with the 190 
genetically inferred CYP2D6 PM phenotype, we present evidence that CYP2D6 PM/IM status 191 
is associated with prolonged gametocyte carriage after treatment. It is currently unclear 192 
whether this has implications for the transmission blocking effects of PQ at population level 193 
in malaria elimination settings. A clinically meaningful effect of genetically inferred CYP2D6 194 
metabolizer status on PQ-induced haemolysis in G6PDd individuals is unlikely.  195 
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Methods: 196 
Study samples 197 
Samples from 8 published clinical trials were used for separate analyses on the impact of 198 
genetically inferred CYP2D6 metabolizer status on PQ safety and efficacy. For analyses on 199 
the impact of CYP2D6 inferred metabolizer status on PQ efficacy, we included samples from 200 
5 PQ efficacy studies. Gametocyte detection was performed following treatment with a 201 
single dose of 0.1-0.75 mg/kg PQ in combination with either artemether-lumefantrine (AL) 202 
(Coartem as standard 6-dose regimen over 3 days; Novartis Pharma, Switzerland) in Burkina 203 
Faso (3) and Uganda (2), or with dihydroartemisinin-piperaquine (DP) (Eurartesim as 204 
standard 3-day regimen; Sigma-Tau, Italy) in Mali (1), The Gambia (4) and Kenya (5). 205 
Analyses on the impact of CYP2D6 inferred metabolizer status on haemolysis were 206 
restricted to G6PD deficient (G6PDd) individuals; we included two additional studies that 207 
specifically assessed PQ safety in G6PD deficient individuals in Mali (20) and The Gambia 208 
(19), using 0.25-0.5 mg/kg PQ in combination with DP. In all studies, haemoglobin (Hb) 209 
concentration in g/dL was measured by self-calibrating HemoCue photometer (Ängelholm, 210 
Sweden). Study details are summarized in Table 1. 211 
 212 
Extraction of nucleic acids 213 
An automated MagNA Pure LC 2.0 Instrument (Roche, Switzerland) was used for extraction 214 
of Total NA or DNA. For the samples from Uganda as well as the parasitology samples from 215 
Mali MagNA Pure LC Total Nucleic Acid Isolation Kit – High Performance, was used. For 216 
Burkina Faso, Kenya and samples from the first season of the trial in the Gambia (both full 217 
blood in EDTA and saliva samples) MagNA Pure LV DNA isolation kits were used. The saliva 218 
samples collected after the second season of the trial in the Gambia were extracted using a 219 
MaxWell 16 Instrument (Promega, USA) and Maxwell 16 DNA Purification kits. 220 
Concentration measurements were done using a NanoDrop (Thermo Fisher, USA) device 221 
(only DNA from full blood in EDTA) and Qubit Fluorometer (Thermo Fisher, USA) with the 222 
Qubit HS (High Sensitivity) kit, which is specific for double-stranded DNA (dsDNA). 223 
 224 
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Gametocyte detection 225 
QT-NASBA was performed as in Schneider et al. (34), qRT-PCR as in Wampfler et al. (35). 226 
Briefly, Total NA, was used for amplification of the P. falciparum mature gametocyte marker 227 
Pfs25 mRNA for the estimation of mature gametocyte density in samples from the clinical 228 
trials. Gametocyte densities were assigned based on plate-specific gametocyte dilution 229 
series, which was diluted in whole blood before extraction of Total NA, as with the samples 230 
from the clinical trials. For samples from trial participants, estimated gametocyte densities 231 
below 0.02 gametocytes per µL were considered to be negative. 232 
 233 
Ethical considerations 234 
Informed consent was obtained from all study participants. The studies received approval 235 
from the Ethics Committee of the Faculty of Medicine, Pharmacy, and Dentistry, University 236 
of Science, Techniques and Technologies of Bamako and the Committee on Human Research 237 
at the University of California, San Francisco (studies in Mali), Comité d'Ethique pour la 238 
Recherche en Santé, Ministère de la Santé du Burkina Faso, Comité Technique d'Examen des 239 
Demandes d'Autorisation d'Essais Cliniques, Ministère de la Santé du Burkina Faso (studies 240 
in Burkina Faso), The Gambia Government/MRC Joint Ethics Committee (studies in The 241 
Gambia), the Makerere University School of Medicine research ethics committee and the 242 
Uganda National Council of Science and Technology (study in Uganda), the Kenya Medical 243 
Research Institute Ethics Review Committee (study in Kenya) and the Interventions Research 244 
Ethics Committee of the London School of Hygiene and Tropical Medicine (all studies).  245 
 246 
CYP2D6 metabolizer status 247 
Samples with a sufficient quantities of DNA (50 ng/µl without or 2,5 ng/µl with 248 
manufacturer provided pre-amplification kit) were genotyped for CYP2D6 *2, *3, *4, *6, *7, 249 
*8, *9, *10, *11, *15, *17, *18, *19, *20, *29, *40, and *41 alleles using OpenArray 250 
technology on a QuantStudio 12K Flex RT PCR system (Life Technologies, Carlsbad, CA, USA). 251 
CYP2D6 copy number was determined with at least one TaqMan copy number assay 252 
targeting intron 2 (Hs04083572_cn), intron 6 (Hs04502394_cn) and/or exon 9 253 
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(Hs00010001_cn) depending on available sample quality and volume. CYP2D6 metabolizer 254 
status was inferred from the genotypes using activity score (AS) (36). An AS of 0.0 = Poor 255 
Metabolizer (PM); 0.5-1.0 = Intermediate Metabolizer (IM); 1.5-2.0 = Extensive Metabolizer 256 
(EM); and > 2.0 = Ultra-rapid Metabolizer (UM) (37). For the analyses, we compared PM/IM 257 
versus EM/UM. 258 
 259 
Statistical analysis 260 
As a single measure of PQ efficacy, we used the presence of gametocytes on either day 7 or 261 
day 10. The effect on Hb was quantified in two ways: day 7 Hb concentration (from studies 262 
with day 7 measurements) and minimum observed Hb concentration (from all studies; up to 263 
day 28 after initiation of treatment). Because different trials used different PQ doses, PQ 264 
dose was categorized as no PQ (control arms), 0.25 mg/kg PQ (0.10-0.25 mg/kg), 0.5 mg/kg 265 
PQ (0.4-0.5mg/kg) or 0.75mg/kg PQ. Anaemia was defined based on criteria of the World 266 
Health Organization (38); moderate anaemia was defined as Hb < 11 g/dL for adults or 267 
<10g/dL for children <5 years of age; severe anaemia was defined as Hb < 8 g/dL for adults 268 
and <7g/dL for children < 5 years of age. Logistic and linear regression models were used to 269 
analyse the effect of CYP2D6 status on gametocyte prevalence, anaemia and Hb 270 
concentration. Models controlled for PQ dose, study, baseline gametocyte and asexual 271 
parasite density (in efficacy analyses), and baseline Hb (in safety analyses). 272 
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Table 1. Trial details and samples available. AL=artemether-lumefantrine, DP=dihydroartemisinin-piperaquine. 288 
Country, 
study type 
Falciparum 
Malaria Status 
G6PDd Status ACT PQ  PQ  Days 
gametocyte 
measurement 
Days 
haemoglobin 
measurement 
CYP2D6  
 
Samples included  
    timing, 
day 
dose 
(mg/kg)  
  Sample 
type, n 
genotyping 
success, % 
(n) 
Efficacy, 
n 
Safety, 
n 
Uganda, 
efficacy (2) 
Uncomplicated 
malaria 
Normal by 
fluorescent 
spot test 
AL 2 0.75 
0.4 
0.1 
0, 2, 3, 7, 10, 
and 14  
 
0, 1, 2, 3, 7, 
10, 14, 21 
50µL EDTA 
blood in L6 
(n=345); 
filter paper 
(n=45) 
58% 
blood in L6 
(n=226); 
filter paper 
(n=2) 
138 11 
Burkina 
Faso 
(Balonghin), 
efficacy (3) 
Asymptomatic 
infection 
Normal by 
rapid 
diagnostic 
test 
AL 2 0.4 
0.25 
0 and 7 0, 1, 2, 3, 7, 
10, 14 
100µL 
EDTA blood 
in 
RNAprotect 
(n=100);  
0.5-1mL 
EDTA blood 
(n=112),  
Oragene 
saliva 
samples 
(n=27) 
57%  
blood in 
RNAprotect 
(n=1) 
EDTA blood 
(n=109) 
Oragene 
saliva 
samples 
(n=27) 
182 8 
Burkina 
Faso 
(Banfora), 
safety (19) 
Asymptomatic 
infection 
Deficient by 
by 
fluorescent 
spot test (and 
controls) 
AL 0 0.4 
0.25 
 
0, 3 and 7 0, 1, 2, 3, 4, 5, 
7, 10, 14, 28 
0.5-1mL 
EDTA blood 
(n=78) 
97% (n=76) 0 43 
Kenya, 
efficacy (5) 
Asymptomatic 
gametocyte 
Regardless of 
G6PD status 
DP 2 0.25 
 
0, 2, 3, 7, and 
14  
0, 2, 3, 7, 14 0.5-1mL 
EDTA blood 
87% 
(n=103) 
99 7 
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carrier (n=118) 
Mali, 
efficacy (1) 
Asymptomatic 
gametocyte 
carrier 
Normal by 
colorimetric 
quantification 
DP 0 0.5 
0.25 
0.125 
0.0625 
0, 2, 3, 7, 14, 
and 28  
0, 1, 2, 3, 7, 
14, 28 
50µL EDTA 
blood in L6 
(n=47); 
Blood 
pellets 
(n=33) 
 
80% 
Blood in L6 
(n=32) 
Blood 
pellets 
(n=32) 
56 4 
Mali, safety 
(20) 
Parasite free 
(by 
microscopy) 
Normal 
controls and 
deficient by 
rapid 
diagnostic 
test 
None 0 0.5 
0.45 
0.4 
None 0, 1, 2, 3, 4, 5, 
6, 7, 8, 9, 10, 
14, 28 
0.5-1mL 
EDTA blood 
(n=28) 
93% 
(n=26) 
0 18 
The Gambia 
efficacy, (4) 
Asymptomatic 
infection 
Normal by 
fluorescent 
spot test 
DP 2 0.75 
0.4 
0.2 
0, 3, 7, 10, 
and 14 
0, 1, 2, 3, 7, 
10, 14, 21, 28, 
35, 42 
Oragene 
saliva 
samples 
(n=85) 
 
99% 
(n=84) 
69 0 
The 
Gambia, 
safety (19) 
Regardless of 
infection 
status 
Deficient by 
fluorescent 
spot test (and 
controls) 
DP 0 0.4 
0.25 
 
0, 3 and 7 0, 1, 2, 3, 4, 5, 
7, 10, 14, 28 
0.5-1mL 
EDTA blood 
(n=58) 
97% 
(n=56) 
0 19 
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Table 2. The effect of CYP2D6 metabolizer status and covariates on gametocyte 290 
prevalence at day 7 or 10 among individuals receiving primaquine 291 
 Gametocytes on day 7 
or 10 / Total (%) 
OR (95% CI) Adjusted OR1 
(95% CI) 
    
CYP2D6 status:  p = 0.028 P = 0.018 
EM/UM 80/289 (28%) 1 1 
PM/IM 51/133 (38%) 1.62 (1.05 – 2.50) 1.79 (1.10 – 2.90) 
    
Baseline gametocyte 
density per ml 
 1.002 (1.000 – 
1.003) p = 0.005 
1.002 (1.001 – 
1.003) p = 0.004 
    
Baseline asexual 
parasite density per ml 
 0.998 (0.994, 
1.002) p = 0.380 
0.994 (0.982, 
0.999) p = 0.025 
    
PQ dose:  p < 0.001 p < 0.001 
0.25 mg/kg 89/228 (39%) 1 1 
0.5 mg/kg 30/153 (20%) 0.38 (0.24 – 0.62) 0.32 (0.18 – 0.56) 
0.75 mg/kg 12/41 (29%) 0.65 (0.31 – 1.33) 0.34 (0.14 – 0.82) 
    
Country:  p < 0.001 p < 0.001 
Burkina Faso 26/166 (16%) 1 1 
Kenya  20/50 (40%) 3.59 (1.78 – 7.26) 2.24 (1.07 – 4.74) 
Mali 21/43 (49%) 5.14 (2.48 – 
10.66) 
6.05 (2.76 – 
13.25) 
Gambia 24/61 (39%) 3.49 (1.80 – 6.78) 3.27 (1.62 – 6.59) 
Uganda 40/102 (39%) 3.47 (1.95 – 6.19) 4.19 (2.03 – 8.64) 
1 Adjusted for all other factors in the table 292 
 293 
 294 
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Figure legends 295 
Figure 1. Genotypically inferred CYP2D6 AS for six African populations. Only samples for 296 
which an exact AS was inferred were included in this figure (n/N where n=number for whom 297 
AS was determined and N=number of samples that genotyping was attempted for). It was 298 
not possible to infer AS for all with determined genotype due to not knowing which 299 
haplotype is duplicated (Dataset S1). In some cases, it was possible to determine an AS 300 
range (Dataset S2) but not an exact  AS. For Mali and The Gambia results from efficacy and 301 
safety studies were combined; in Burkina Faso the efficacy and safety studies were carried 302 
out in two distinct populations in different areas and therefore the AS results are presented 303 
separately for the Balonghin and Banfora populations. 304 
 305 
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